CRL vs MBX · rev $2.00B vs $1.98B cap
Charles River Laboratories (CRL) versus MBX Biosciences, Inc. Common Stock (MBX) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
MBX Biosciences, Inc. Common Stock (MBX) is a biotechnology company listed on NASDAQ.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
MBX does not have a complete income-statement cache yet.
CRL currently screens at market cap $7.78B. MBX currently screens at market cap $1.98B.
Not investment advice. Open the CRL and MBX stock pages for the full models.
Not investment advice.